MED Earnings

MED reported its FY2025Q4 earnings on 2026-02-23, showcasing a revenue of 0.00 against an estimate of 108.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.76 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following MED's FY2025Q4 earnings announcement on 2026-02-23, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, MED's stock price tends to shift by an average of -1.92% in the 10 days leading up to earnings and -9.14% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate MED’s annual revenue to reach 71.00M, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between MED's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MED's stock price typically moves by -1.92% in the 10 days before its earnings and -9.14% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -1.00 and revenue of 71.00M.

The earnings call highlighted significant challenges, including a 36.2% revenue decline, increased SG&A expenses, and a net loss, indicating financial strain. Despite optimistic guidance on coach productivity and new programs, economic uncertainties and competition pose risks. The Q&A session revealed unclear management responses, adding to investor concerns. Although there are plans for product evolution and a focus on metabolic health, the lack of immediate positive catalysts and the absence of a market cap suggest a negative stock price movement in the short term.